Jennifer Klomp , PhD

Assistant Professor

Medicine
Pharmacology & Toxicology

400 Monroe Ave NW
Grand Rapids, MI

Biography

I am an Assistant Professor in the Department of Medicine at Michigan State University College of Human Medicine. My research focuses on understanding and defining methods to target aberrant kinase signaling downstream of oncogenic KRAS in pancreatic cancer. Kinases of interest: ERK, CHK1, SRC; Microscopy, protein engineering, molecular biology.

Education

Doctor of Philosophy , Pharmacology, University of Illinois at Chicago, 2012
Master's of Science, Biology, Central Michigan University, 2005
Bachelor's of Science, Biology/Chemistry, Grand Valley State University, 2001

Employment

Assistant Professor, Henry Ford Health + Michigan State University Health Sciences, East Lansing, 2024 - Present
Postdoctoral Fellow, University of North Carolina, Chapel Hill, 2017 - 2024
PhD Candidate/ Graduate Research Assistant/ Graduate Teaching Assistant, University of Illinois at Chicago, Chicago, 2012 - 2017
Senior Research Technician, Van Andel Research Institute, Grand Rapids, 2007 - 2012
Research/Teaching Assistant, Central Michigan University, Mount Pleasant, 2006 - 2007
Undergraduate Researcher , Grand Valley State University, Allendale, 2003 - 2004

Publications

Data from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer (2025)

Fundings

Integrated Training in Cancer Model Systems

Defining the roles of ERK MAPK in driving KRAS-mutant pancreatic cancer growth

Training Program in Lung Biology and Pathobiology

Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer